JAN 05, 2017
Pfizer today announced positive top-line results for its potential biosimilar to adalimumab (Humira).
The multinational, randomized, double-blind, two-arm, parallel group equivalence study evaluated the biosimilar compared with adalimumab in combination with methotrexate to treat patients with moderate to severe rheumatoid arthritis. At week 12, the biosimilar demonstrated equivalent efficacy, as measured by the American College of Rheumatology 20 (ACR20) response rate.
Adalimumab is currently approved in the US, EU and other markets for multiple indications including noninfectious intermediate, posterior and panuveitis